Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oral Butyrate Supplementation in MASLD
NCT06759363Phase 3Enrolling by invitation
- Sponsor
- Clinical Hospital Center Zvezdara
- Start
- Jan 2024
- Primary completion
- Dec 2024
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 3 trial of sodium butyrate, calcium butyrate in metabolic dysfunction-associated steatotic liver disease (MASLD), sponsored by Clinical Hospital Center Zvezdara. Started Jan 2024; status: enrolling by invitation.
02
Drugs
sodium butyratecalcium butyrate
03
Conditions
metabolic dysfunction-associated steatotic liver disease (MASLD)
Beyond the preview
Go deeper on NCT06759363.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06759363.